North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: WDC Cosmetic and Research, Wilmington, North Carolina
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
Recruiting
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Ava... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/21/2025
Locations: North Carolina Retina Associates, Cary, North Carolina
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of North Carolina at Chapel Hill Cancer Center, Chapel Hill, North Carolina
Conditions: Advanced Solid Tumor
Register for Updates
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
NCT06634381
Recruiting
The purpose of this research study is to better understand how cancer-related fatigue affects patients and how it's discussed with providers. This information will be used to develop an educational resource (visual aid poster) that could help individuals and their providers talk about cancer-related fatigue and which may help individuals better manage this symptom.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Levine Childrens Hospital Pediatric Cancer and Blood Disorders, Charlotte, North Carolina
Conditions: Cancer, Fatigue
Register for Updates
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
NCT06580106
Recruiting
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM
NCT06565156
Recruiting
This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amniotic Membrane (BR-AM) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for debridement, wound dressings, and offloading. Weekly subject visits will help monitor compliance i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Site 15, Chapel Hill, North Carolina
Conditions: Non-infected Diabetic Foot Ulcer, Diabetic Foot, Diabetic Wound, Diabetic Foot Ulcer, Non-ischemic Diabetic Foot Ulcer
Register for Updates
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
NCT06489041
Recruiting
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Cancer, Gastrointestinal Cancer
Register for Updates
LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer
NCT06464562
Recruiting
Patients are living longer with metastatic lung cancer (i.e., metavivors) due to therapeutic advances, but face significant challenges. Most metavivors will ultimately die of cancer and must navigate the duality of living while dying. Unsurprisingly, metavivors endorse high psychological distress (e.g., anxiety, depression, illness non-acceptance), high symptom burden (e.g., fatigue, dyspnea, pain), and poor quality of life. Psychosocial interventions can improve outcomes, but existing paradigms... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Cancer Metastatic to Lung
Register for Updates
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141
Recruiting
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
NCT06375811
Recruiting
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
07/21/2025
Locations: Duke Fertility, Morrisville, North Carolina
Conditions: Infertility, Endometriosis
Register for Updates
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
NCT06359379
Recruiting
This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Glioblastoma, IDH-wildtype
Register for Updates
INHANCE Stemless Reverse Shoulder IDE
NCT06323980
Recruiting
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/21/2025
Locations: OrthoCarolina Research Institute Charlotte, Charlotte, North Carolina
Conditions: Arthroplasty, Replacement, Shoulder
Register for Updates